Successful treatment of systemic lupus erythematosus with residual disease activity by switching from belimumab to anifrolumab.

Umeda, Masataka; Kojima, Kanako; Michitsuji, Toru; Tsuji, Yoshika; Shimizu, Toshimasa; Fukui, Shoichi; Sumiyoshi, Remi; Koga, Tomohiro; Kawashiri, Shin-Ya; Naoki, Iwamoto; Iagawa, Takashi; Tamai, Mami; Origuchi, Tomoki; Furuyama, Masako; Tsuboi, Masahiko; Matsuoka, Naoki; Okada, Akitomo; Aramaki, Toshiyuki; Kawakami, Atsushi

Umeda, Masataka; Kojima, Kanako; Michitsuji, Toru; Tsuji, Yoshika; Shimizu, Toshimasa; Fukui, Shoichi; Sumiyoshi, Remi; Koga, Tomohiro; Kawashiri, Shin-Ya; Naoki, Iwamoto; Iagawa, Takashi; Tamai, Mami; Origuchi, Tomoki; Furuyama, Masako; Tsuboi, Masahiko; Matsuoka, Naoki; Okada, Akitomo; Aramaki, Toshiyuki; Kawakami, Atsushi.

Afiliación

Umeda M; Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Kojima K; Research Unit for Preventive and Clinical Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Michitsuji T; Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Tsuji Y; Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Shimizu T; Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Fukui S; Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Sumiyoshi R; Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Koga T; Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Kawashiri SY; Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Naoki I; Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Iagawa T; Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Tamai M; Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Origuchi T; Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Furuyama M; Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Tsuboi M; Department of Rheumatology, Nagasaki Kita Hospital, Nagasaki, Japan.
Matsuoka N; Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan.
Okada A; Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan.
Aramaki T; Department of Rheumatology, National Hospital Organization Nagasaki Medical Center, Omura, Japan.
Kawakami A; Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan.

Mod Rheumatol ; 2024 May 04.

Article en En | MEDLINE | ID: mdl-38756072

Palabras clave

Anifrolumab; belimumab; biologics; systemic lupus erythematosus; treatment switching

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Mod Rheumatol Año: 2024 Tipo del documento: Article País de afiliación: Japón